@article {Archimandritis:April 2005:0300-7995:603,
author = "Archimandritis, Athanasios J.",
author = "Nikolopoulou, Vassiliki",
author = "Kouklakis, Georgios",
author = "Paraskevas, Emanouil",
author = "Avgerinos, Alexandros",
author = "Tsianos, Epaminontas",
author = "Triantafillidis, John K.",
title = "Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study",
journal = "Current Medical Research and Opinion",
volume = "21",
year = "April 2005",
abstract = "Background: In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD).Aim: To examine symptom relief during week 1 of rabeprazole therapy, in addition to GORD healing, in a clinical practice setting.Methods: In this 8-week, prospective, multicentre, postauthorisation surveillance study conducted in Greece, patients with GORD (intent-to-treat: efficacy, 272; safety, 273) were treated with rabeprazole 20mg once daily. The primary efficacy end point was the change from baseline in GORD symptom severity on day 1, 2, 3 and 7 using a 5-point Likert scale (1 = no symptoms; 5 = severe symptoms). Oesophageal healing was also evaluated by comparing the results of endoscopic findings at baseline and after 4 and 8 weeks of treatment.Results: On day 1 of treatment, rabeprazole relieved GORD symptoms across all grades of oesophagitis, with statistically significant (p = 0.0001) improvement in heartburn, regurgitation, epigastric pain and dysphagia. Oesophageal healing was achieved in 77% of patients at week 4 and in 90% at week 8 and treatment was well tolerated.Conclusions: In a clinical practice setting, rabeprazole provided rapid relief of GORD symptoms, confirming results seen in controlled clinical trials.",
pages = "603-610(8)",
url = "http://www.ingentaconnect.com/content/apl/cmro/2005/00000021/00000004/art00018"
doi = "doi:10.1185/030079905X41444"
}